EC Committee concludes that hydroxyapatite (nano) in cosmetic products may present a risk to consumers | Bergeson & Campbell, CP


On April 12, 2021, the European Commission (EC) Scientific Committee for Consumer Safety (CSSC) published its final opinion on hydroxyapatite (nano). The EC asked whether the SCCS considers the nanomaterial hydroxyapatite to be safe when used in leave-in and rinse-off dermal and oral cosmetics at maximum concentrations and reported specifications, taking into account reasonable exposure conditions. predictable. The SCCS states that after reviewing the data provided, and other relevant information available in the scientific literature, it “cannot conclude on the safety of hydroxyapatite composed of rod-shaped nanoparticles for use in products. oral care cosmetics at the maximum concentrations and specifications stated in this notice. Indeed, the data and information available are not sufficient to exclude concerns regarding the genotoxic potential of hydroxyapatite (nano). The EC also asked if the SCCS had any other scientific concerns regarding the use of hydroxyapatite in nano form in cosmetic products. The notice states that, although the particle shape of the nanomaterial considered in this notice is reported to be rod-shaped, “SCCS is aware that depending on the manufacturing process, needle-shaped PAH nanoparticles may also be be produced ”. According to the Opinion, the available information indicates that hydroxyapatite (nano) in needle form “is of concern for potential toxicity” and “should not be used in cosmetic products”. The SCCS concluded that there is concern that the use of hydroxyapatite (nano) in cosmetic products “may present a risk to the consumer”.

[View source.]


Comments are closed.